Compare Abbott Laboratories (ABT) vs Tapestry, Inc. (TPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Tapestry, Inc. — how do they compare? Abbott Laboratories trades at $95.86 (market cap $166.94B), while Tapestry, Inc. trades at $139.22 (market cap $29.40B). The key difference: Abbott Laboratories is far larger — about 5.7× Tapestry, Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | TPR | |
|---|---|---|
Market Cap | $166.94B | $29.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $160.49 |
52-Week Low | $82.57 | $92.20 |
Enterprise Value | $193.69B | $32.25B |
Dividend Yield | 2.63% | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
TPR trades at $146.3, up 1.45% today, with a bullish technical signal and strong analyst support. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.66 exceeding the $1.30 estimate. The company maintains high profitability margins, including a 76.18% gross margin and 55.74% ROE, though net income margin declined to 8.44% in 2025. Positive news highlights digital growth and Gen Z engagement, with a consensus price target of $184.14 implying significant upside.
Outlook is positive given earnings momentum and analyst optimism, but risks include high debt levels, volatile cash flows, and competitive pressures in the luxury retail sector. The stock's elevated P/E of 44.36 requires sustained growth to justify valuation, while institutional ownership trends and insider activity should be monitored for confirmation of bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
